PML/RARa (AML - M3) (APL) Quantitative, in Visit Clinic

Acute promyelocytic leukemia (APL) with PML-RARA is a subtype of acute myeloid leukemia caused by a PML‑RARA gene fusion (t(15;17)) that blocks promyelocyte maturation. It commonly causes life‑threatening coagulopathy and bleeding. APL is highly treatable but requires urgent therapy—typically all‑trans retinoic acid plus arsenic trioxide—to induce differentiation, prevent early hemorrhage, and achieve high remission rates.

Yes. Acute promyelocytic leukemia (AML M3) is one of the most curable AML subtypes. Modern targeted therapy—all‑trans retinoic acid (ATRA) combined with arsenic trioxide, with chemotherapy in some cases—produces long‑term remission and cure in roughly 80–90% of patients, especially low‑risk cases. Early diagnosis and prompt treatment with close monitoring for complications are essential.

The APML RARA test detects the PML‑RARA fusion gene from the t(15;17) translocation in acute promyelocytic leukemia (APML). It confirms diagnosis, guides targeted therapy (for example ATRA and arsenic), and monitors treatment response or minimal residual disease. Testing is performed on blood or bone marrow using molecular methods (RT‑PCR) and cytogenetics (FISH or karyotype).

M3 in leukemia denotes acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia characterized by accumulation of abnormal promyelocytes and the t(15;17) PML‑RARA fusion. APL often presents with bleeding due to coagulopathy and risk of disseminated intravascular coagulation. It requires prompt treatment with all‑trans retinoic acid (ATRA), often combined with arsenic trioxide or chemotherapy, and has a favorable prognosis with modern therapy.

Acute promyelocytic leukemia (APL) is a medical emergency because it commonly causes dangerous bleeding from coagulopathy and can progress rapidly. Historically fatal, modern targeted treatment (ATRA plus arsenic trioxide) yields high complete-remission and cure rates—often over 80–90%—if started promptly. Early death from bleeding or differentiation syndrome remains a risk, so urgent diagnosis, specialized care, and close monitoring are essential.

High-risk APL is acute promyelocytic leukemia with a presenting white blood cell count >10 × 10^9/L. It is associated with higher risk of early life‑threatening complications — severe coagulopathy/bleeding, leukostasis, and differentiation syndrome — and usually requires intensified therapy, close inpatient monitoring, and aggressive supportive care (transfusions and prompt targeted treatment) to reduce early mortality.